NCT05410730View on ClinicalTrials.gov

A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

November 23, 2022

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2027

Conditions
High-risk NMIBC
Interventions
DRUG

SHR-1501

SHR-1501 single agent dose escalation, and in combination of BCG or SHR-1316.

Trial Locations (1)

100034

RECRUITING

Peking University First Hospital, Beijing

All Listed Sponsors
lead

Shanghai Hengrui Pharmaceutical Co., Ltd.

INDUSTRY